Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Kindly MD, Inc. filed an 8-K reporting current beneficial ownership information for its common stock and tradeable warrants. The filing lists individual holdings for directors and executive officers and aggregates that all officers and directors as a group hold 21,798,017 shares, representing 5.80% of the outstanding common stock. It also discloses a significant institutional holder, Verition Multi-Strategy Master Fund Ltd., owning 37,781,847 shares, equal to 9.99% of the company. The filing is a routine ownership disclosure showing insider positions and a near-10% outside stake, without other transaction, financial performance, or management-change detail.
Kindly MD, Inc. (NAKA) filed an S-3ASR describing securities offerings, post‑merger capital changes and risk factors. The filing discloses the company may use proceeds for a Bitcoin Treasury Strategy, working capital, debt repayment, acquisitions, capital expenditures, projects or share repurchases. It lists detailed terms that may govern future debt securities, warrants, rights and units. The company warns of costs and potential litigation from the Merger, post‑closing volatility in its stock, future dilution from outstanding warrants, a convertible debenture and PIPE issuances, operational and regulatory risks (including implementing a bitcoin treasury operation and crypto regulation risks), and cyber and IP risks. The Registrant states its common stock trades on Nasdaq under NAKA and references recent SEC filings and exhibits that update its capital stock description.
Kindly MD, Inc. filed an amended Current Report (Form 8-K/A) that attaches exhibit-level disclosures for Nakamoto Holdings, Inc. The filing identifies the company's trading symbols as NAKA on The Nasdaq Stock Market LLC and NAKAW on the OTC Pink Market. It includes the consent of Wolf & Company, P.C., audited financial statements of Nakamoto as of April 30, 2025 and for the period from March 6, 2025 (inception) to April 30, 2025, unaudited financials as of June 30, 2025, unaudited pro forma condensed combined financial statements reflecting the acquisition of Nakamoto, supplemental risk factors, and management discussion and analysis for the stated periods. The filing is executed by CEO David Bailey.
Tyler Matthew Evans, identified as Chief Investment Officer and a director of Kindly MD, Inc. (NAKA), reported on Form 4 that on 08/14/2025 he acquired 2,232,114 shares of the issuer’s common stock at a reported price of $0, increasing his total beneficial ownership to 2,410,685 shares. The filing is signed on 08/22/2025. The form shows a non-derivative acquisition only and provides no additional explanatory detail about the mechanics or consideration for the transaction.
Kindly MD, Inc. (NAKA) Form 3: Tyler Matthew Evans filed an initial Form 3 disclosing direct beneficial ownership of 178,571 shares of Kindly MD common stock. The filing lists Evans as a Director, an Officer (Chief Investment Officer), and not a 10% owner. The Form 3 reports the event date of 08/14/2025 and is signed on 08/22/2025.
Kindly MD, Inc. (NAKA) director Charles Phillip Blackburn filed an Initial Statement of Beneficial Ownership (Form 3) reporting no securities beneficially owned as of the event date 08/14/2025. The filing lists Blackburn's address in Salt Lake City and indicates the form was signed on 08/21/2025. The document includes an Exhibit 24 power of attorney reference.
The filing reports that Andrew Creighton, serving as Chief Compliance Officer and a director of Kindly MD, Inc. (ticker: NAKA), executed a transaction on 08/14/2025 acquiring 2,232,114 shares of the issuer's common stock at a reported price of $0. Following the reported acquisition, Mr. Creighton beneficially owns 3,124,971 shares. The Form 4 was signed by Mr. Creighton on 08/19/2025. No derivative securities were reported on this form and no additional explanatory text about the nature of the $0 price was provided in the filing.
Kindly MD, Inc. (NAKA) reporting person Andrew Creighton disclosed direct beneficial ownership of 892,857 shares of common stock on a Form 3 filed for the 08/14/2025 event. The filing identifies Mr. Creighton as a director and as Chief Compliance Officer and is signed 08/19/2025. The Form 3 documents initial ownership and includes Exhibit 24 (Power of Attorney).
David F. Bailey, who is listed as both Chief Executive Officer and a Director of Kindly MD, Inc. (NAKA), reported a transaction dated 08/14/2025 on Form 4. The filing shows an acquisition of 11,160,572 shares of Common Stock at a reported price of $0. Following the transaction, Mr. Bailey is reported to beneficially own 11,160,572 shares in a direct ownership form. The Form 4 is signed by Mr. Bailey on 08/15/2025.
Kindly MD, Inc. filed a Form 25 to remove its tradeable warrants to purchase shares of common stock (Nasdaq: NAKAW) from listing on The Nasdaq Stock Market LLC. This action relates specifically to the warrant class, not the underlying common stock, and is a formal step in ending exchange trading and/or registration of these warrants under Section 12(b) of the Securities Exchange Act of 1934.